1593 completed, 480 unknown, 436 recruiting, 301 terminated. 896 Not applicable, 748 Phase 2, 484 Phase 1, 334 Phase 3, 217 Phase 4.
Follow Urinary Bladder Diseases: new trials by email Literature Review of Urinary Bladder Diseases trials Research Report on Urinary Bladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer | Not applicable | Not yet recruiting | Chinese University of Hong Kong | 60 | 2028-07-31 | 2026-07-22 |
| Device for Bladder Control for Men With SCI Noninvasive electrical stimulation device to improve bladder control - Neurogenic Bladder | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 12 | 2028-06-01 | 2026-06-25 |
| Empowerment Program to Reduce Treatment of Asymptomatic Bacteriuria in Veterans With Spinal Cord Injury Empowerment Program - Spinal Cord Injury, Spinal Cord Disease | Not applicable | Not yet recruiting | VA Office of Research and Development | 30 | 2027-08-02 | 2026-08-19 |
| Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS) Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] - Vesico-Ureteral Reflux | Phase 1 | Not yet recruiting | Boston Children's Hospital | 70 | 2027-07-01 | 2026-07-22 |
| Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children Urgent PC - Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Not yet recruiting | Chi Dang Hornik | 50 | 2027-04-01 | 2026-06-17 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC. Hyperthermic intravesical chemotherapy (HIVEC) - Non-muscle Invasive Bladder Cancer (NMIBC) | Not applicable | Not yet recruiting | Eight Medical International BV | 30 | 2027-01-01 | 2026-08-14 |
| VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors Low Intensity Surveillance, High Intensity Surveillance - High-Grade Early-Stage Bladder Cancer | Not applicable | Not yet recruiting | VA Office of Research and Development | 2482 | 2027-01-01 | 2026-02-13 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-10-01 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| Efficacy and Safety of Pregabalin Combined With Educational and Behavioral Intervention for Bladder Pain Syndrome/Interstitial Cystitis Educational and Behavioral Management Program (EBMP), Pregabalin - Bladder Pain Syndrome, Pregabalin | Phase 1 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-12-31 | 2026-08-07 |
| Venlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome Venlafaxine oral tablet combined with Education and Behavioral Modification Program (EBMP), Education and Behavioral Modification Program (EBMP) only - Bladder Pain Syndrome, Chronic Pelvic Nociplastic Pain | Phase 1 | Not yet recruiting | Beijing Tiantan Hospital | 140 | 2026-12-31 | 2026-07-13 |
| A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer Vepugratinib - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 161 | 2026-12-01 | 2026-10-08 |
| Peroneal Neuromodulation vs Pelvic Floor Exercises in OAB Transcutaneous Peroneal Electrical Neuromodulation, Pelvic Floor Exercise - Overactive Bladder (OAB), Neuromodulation | Not applicable | Not yet recruiting | Marmara University | 60 | 2026-12-01 | 2026-08-26 |
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
Showing 20 of 3280. Sign in to see all of them.
Urinary Bladder Neoplasms (1723) · Urinary Bladder, Overactive (801) · Non-Muscle Invasive Bladder Neoplasms (282) · Cystitis, Interstitial (231) · Carcinoma, Transitional Cell (207) · Prostatic Neoplasms (198) · Urinary Bladder, Neurogenic (182) · Neoplasms (168) · Breast Neoplasms (167) · Urinary Incontinence (167) · Lung Neoplasms (155) · Ovarian Neoplasms (154) · Carcinoma, Non-Small-Cell Lung (153) · Stomach Neoplasms (144) · Pancreatic Neoplasms (136)
Female Urogenital Diseases and Pregnancy Complications (3278) · Female Urogenital Diseases (3276) · Urogenital Diseases (3274) · Male Urogenital Diseases (3269) · Urologic Diseases (3232) · Neoplasms by Site (1859) · Urogenital Neoplasms (1841) · Urologic Neoplasms (1814) · Neoplasms (1707) · Pathological Conditions, Signs and Symptoms (1428) · Signs and Symptoms (1117) · Urological Manifestations (886) · Lower Urinary Tract Symptoms (815) · Neoplasms by Histologic Type (724)
Gemcitabine (181) · Cisplatin (120) · Solifenacin Succinate (91) · pembrolizumab (90) · mirabegron (82) · Botulinum Toxins, Type A (77) · Tolterodine Tartrate (59) · Mitomycin (55) · Cystectomy (47) · Docetaxel (45) · Carboplatin (44) · Nivolumab (43) · Paclitaxel (41) · fesoterodine (38) · Magnetic Resonance Spectroscopy (37)
National Cancer Institute (NCI) (66) · Memorial Sloan Kettering Cancer Center (50) · Pfizer (49) · Astellas Pharma Inc (46) · Mansoura University (42) · M.D. Anderson Cancer Center (34) · Allergan (33) · Merck Sharp & Dohme LLC (23) · Assiut University (21) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (21) · Mayo Clinic (20) · AstraZeneca (19) · National Taiwan University Hospital (19) · Samsung Medical Center (19) · Seoul National University Hospital (18)
United States (1485) · France (260) · Canada (253) · China (244) · United Kingdom (217) · Italy (192) · Spain (190) · South Korea (189) · Germany (160) · Turkey (Türkiye) (144) · Netherlands (141) · Belgium (129) · Denmark (121) · Australia (114) · Poland (112)
Hann-Chorng Kuo, M.D. (11) · Kenneth Peters, MD (10) · Rose Khavari, MD (9) · Ho-Hsiung Lin, PhD (8) · Kyu-Sung Lee, Ph.D (8) · Ahmed Mosbah, MD (7) · Andrea B Apolo, M.D. (7)
PMID 37160401, PMID 32734597, PMID 37811598, PMID 17049716, PMID 19941278, PMID 28754926, PMID 35881009, PMID 12559262, PMID 34125951, PMID 38045238, PMID 38167321, PMID 12811491, PMID 16389183, PMID 24246044, PMID 26337427, PMID 26573101, PMID 27939400, PMID 29562804, PMID 32791124, PMID 36148895, PMID 37068952, PMID 37947276, PMID 11001674, PMID 11857671, PMID 12118019, PMID 15540753, PMID 16406907, PMID 16804634, PMID 17340590, PMID 17409436, PMID 17452976, PMID 18092336, PMID 18490916, PMID 18499184, PMID 19097774, PMID 19687335, PMID 19937315, PMID 19949018, PMID 20035977, PMID 20850152, PMID 21293089, PMID 21831711, PMID 22002018, PMID 22258963, PMID 22280855, PMID 22415792, PMID 22464310, PMID 22512481, PMID 22877502, PMID 23036134
2023 (27), 2017 (21), 2019 (14), 2014 (12), 2018 (12), U10CA032102 (10), 2015 (9), 2009 (8), 2016 (8), 2025 (6), P30CA014089 (6), P30CA015704 (6), P50CA091846 (5), U10CA031946 (5), P30CA138292 (4)